Sironax is advancing enrollment in its Phase 2 FORGE-LM clinical trial evaluating SIR4156, a first-in-class NAMPT (nicotinamide phosphoribosyltransferase) activator, as a novel obesity intervention. The trial's core hypothesis positions SIR4156 as a candidate that could address one of the most clinically significant drawbacks of current weight-management therapies: the loss of lean body mass alongside fat.
The Mechanism
NAMPT is the rate-limiting enzyme in the NAD⁺ biosynthesis salvage pathway, and activating it is thought to enhance cellular energy metabolism in muscle and adipose tissue. Unlike GLP-1 receptor agonists — currently the dominant pharmacological approach in the weight-management category — NAMPT activation targets a fundamentally different metabolic axis. The lean-mass preservation endpoint is particularly significant: real-world data from GLP-1 users has increasingly shown that a substantial portion of total weight lost can come from muscle, raising concerns among clinicians and fueling demand for adjunct or alternative solutions across both pharmaceutical and functional nutrition channels.
Market Context
The obesity and weight-management market has become one of the fastest-moving segments in health and wellness, with the GLP-1 drug class alone reshaping adjacent categories including protein supplementation and functional foods positioned for satiety and muscle support. Operators and formulators are racing to develop products that complement — or differentiate from — GLP-1 pharmacotherapy, particularly around lean-mass retention, micronutrient repletion, and metabolic support. A clinically validated small-molecule NAMPT activator could eventually inform ingredient and adjunct-therapy strategies well beyond the pharmaceutical pipeline, with implications for nutraceutical ingredient developers monitoring novel mechanisms in NAD⁺ biology.
What's Next
The FORGE-LM designation signals that lean mass preservation is a primary clinical endpoint, not a secondary observation — a meaningful distinction for trial design credibility. Sironax has not disclosed Phase 2 enrollment targets, dosing parameters, or a projected readout timeline in the available release. As the trial matures, data on the compound's safety profile, bioavailability, and efficacy against both body composition and standard weight-loss endpoints will be closely watched by the broader metabolic health investment and ingredient community. For functional food and supplement operators tracking the science underpinning next-generation weight-management ingredients, the NAMPT pathway represents an emerging research frontier worth monitoring.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.